Canadian Court Blocks Generic Celebrex Launch

Law360, New York (May 1, 2007, 12:00 AM EDT) -- A Canadian appeals court has upheld patents for painkiller Celebrex that prevent the launch of a generic version of the drug until November 2014, Pfizer Inc. said Tuesday.

The Federal Court of Appeal of Canada reversed a lower court ruling that permitted Teva Pharmaceuticals’ Canadian subsidiary Novopharm from launching its version of Celebrex. The appellate court’s order prohibits regulatory approval of a generic Celebrex until Pfizer’s patents regarding the drug’s compound expire in 2014.

“Without appropriate protection of intellectual property, Pfizer and other research-based pharmaceutical companies...
To view the full article, register now.